NEW YORK — Precision medicine-focused AI firm Aignostics said Tuesday that it has raised $34 million in a Series B financing round.
The round was led by Athos with participation from the Mayo Clinic and High-Tech Gründerfonds, as well as existing investors Wellington Partners, Boehringer Ingelheim Venture Fund, Carma Fund, and IBB Ventures-managed VC Fonds Technologie.
Aignostics said that it will use the new funding to expand its pipeline of computational pathology products, including ones for tumor microenvironment and biomarker profiling, and to grow its US-based workforce. It will also use the money to develop foundation models and biopharma products in collaboration with the Mayo Clinic.
Founded in 2018 as a spinoff of Charité Berlin, Aignostics develops AI technologies to analyze a range of pathology data derived from tissue samples including next-generation sequencing, immunohistochemistry, proteomic, and spatial transcriptomic data.
The Berlin, Germany-based company — which also has a New York office — uses the technologies to support clients' drug-discovery and companion diagnostic development efforts, translational research, and clinical trials. In early 2022, it began working with Ultivue on the development of spatial multiplexed biomarker tools. It has also formed partnerships with Bayer and Virchow Laboratories.
Aignostics said it has raised over $55 million to date.